Beyond Air, Inc. (NASDAQ:XAIR – Get Free Report) Director Erick Lucera purchased 39,266 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was acquired at an average price of $0.40 per share, with a total value of $15,706.40. Following the completion of the purchase, the director now owns 43,608 shares in the company, valued at $17,443.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Beyond Air Stock Up 26.1 %
NASDAQ:XAIR opened at $0.47 on Friday. The firm has a market cap of $21.71 million, a P/E ratio of -0.26 and a beta of -0.10. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.61 and a current ratio of 3.80. Beyond Air, Inc. has a fifty-two week low of $0.36 and a fifty-two week high of $3.35. The firm has a 50-day simple moving average of $0.70 and a two-hundred day simple moving average of $1.23.
Beyond Air (NASDAQ:XAIR – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.12. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.72 million. Beyond Air had a negative net margin of 5,197.76% and a negative return on equity of 203.12%. During the same period last year, the business earned ($0.45) EPS. Analysts predict that Beyond Air, Inc. will post -1.01 earnings per share for the current fiscal year.
Institutional Trading of Beyond Air
Analysts Set New Price Targets
Several research analysts recently issued reports on the stock. BTIG Research lowered shares of Beyond Air from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 25th. Roth Mkm reiterated a “buy” rating and issued a $2.00 price target on shares of Beyond Air in a research note on Friday. Piper Sandler decreased their price target on shares of Beyond Air from $3.50 to $1.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Roth Capital raised shares of Beyond Air to a “strong-buy” rating in a research report on Friday. Finally, Truist Financial reduced their price objective on shares of Beyond Air from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, April 30th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $3.67.
Read Our Latest Report on Beyond Air
Beyond Air Company Profile
Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.
See Also
- Five stocks we like better than Beyond Air
- What is a Dividend King?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MarketBeat Week in Review – 8/12 – 8/16
- There Are Different Types of Stock To Invest In
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.